ANI Pharmaceuticals (ANIP) Q2 2024 earnings summary

Executive summary

• Achieved record Q2 2024 revenues of $138.0 million, up 18.4% year-over-year, driven by rare disease (Cortrophin Gel) and generics growth.

• Announced proposed acquisition of Alimera Sciences, expected to close in Q3 2024, adding ILUVIEN and YUTIQ to the rare disease portfolio and expanding international reach.

• Raised full-year 2024 guidance for net revenues, Cortrophin Gel sales, adjusted EBITDA, and EPS.

• Net loss for Q2 2024 was $(2.7) million, compared to net income in the prior year, due to higher costs and acquisition-related expenses.

• Generics business delivered high-teens growth, offset by a decline in Established Brands.

Financial highlights

• Q2 2024 net revenues: $138.0 million (+18.4% YoY); adjusted non-GAAP EBITDA: $33.2 million; adjusted non-GAAP EPS: $1.02.

• Rare Disease segment (Cortrophin Gel) revenue: $49.2 million (+102.4% YoY); Generics revenue: $74.0 million (+16.8% YoY); Established Brands revenue: $14.9 million (-48.5% YoY).

• Q2 2024 operating expenses rose 27.6% YoY to $132.9 million, driven by higher cost of sales and SG&A.

• Q2 2024 gross margin: 58.2%–58.4% (down from 63.7% YoY); adjusted non-GAAP EBITDA decreased 2.6% YoY to $33.2 million.

• Cash and cash equivalents at June 30, 2024: $240.1 million; outstanding debt: $292.5 million.

Outlook and guidance

• Full-year 2024 net revenue guidance raised to $540–$560 million, 11–15% YoY growth.

• Cortrophin Gel revenue guidance increased to $185–$195 million, 65–74% YoY growth.

• Adjusted non-GAAP EBITDA guidance raised to $140–$150 million; adjusted non-GAAP EPS guidance increased to $4.38–$4.82.

• Gross margin guidance slightly reduced to 61–62% due to new manufacturing suite ramp-up.

• Guidance excludes contribution from pending Alimera acquisition.